Eighty-six patients with ureteral colic were included in a randomised, prospective, double-blind study of the analgesic efficacy and tolerance of ketoprofen versus diclofenac, both administered intramuscularly. There were no significant differences regarding pain-relief or side-effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/00365599309180441 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Open observational study with a retrospective analysis of the efficacy and tolerability of aceclofenac in patients with acute non-specific low back pain].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
Clinical Hospital of St. Luka, St. Petersburg, Russia.
Objective: To analyze the efficacy and tolerability of aceclofenac in the treatment of patients with acute non-specific musculoskeletal pain in the lower back (ANBP) compared with other NSAIDs (dexketoprofen, nimesulide and lornoxicam), as well as to assess the impact of NSAIDs therapy on the relative risk of recurrence and chronicity of this pathology.
Material And Methods: The study involved 80 patients (47 women and 33 men), average age 52.6 [47.
Optogenetic screening of MCT1 activity implicates a cluster of non-steroidal anti-inflammatory drugs (NSAIDs) as inhibitors of lactate transport.
PLoS One
December 2024
Department of Molecular Biology, Princeton University, Princeton, New Jersey, United States of America.
Article Synopsis
- - Lactate transport is vital for cancer cell survival, but current drugs targeting the MCT1 and MCT4 transporters have shown limited success in clinical applications, mostly due to issues with isoform expression in tumors and the lengthy time required for new inhibitors to reach human trials.
- - Researchers conducted a drug screen using FDA-approved substances to find potential MCT inhibitors, identifying that several drug classes, including non-steroidal anti-inflammatory drugs (NSAIDs), can inhibit MCT1 with moderate effectiveness.
- - Specifically, among continuing investigations on NSAIDs for their ability to inhibit MCT1, piroxicam emerged as a promising candidate with relevant dosages that could enhance anticancer therapy by potentially working alongside existing treatments.
Real-world usage pattern, effectiveness and safety of oral tramadol/dexketoprofen trometamol fixed-dose combination in moderate-to-severe acute pain in Asia: a prospective, multicentre, observational study.
BMJ Open
October 2024
Medical Affairs, A Menarini Asia Pacific Holdings Pte Ltd, Singapore.
Objectives: This study aims to determine the usage pattern, effectiveness and safety of oral tramadol 75 mg and dexketoprofen trometamol 25 mg fixed-dose combination (TRAM/DKP FDC) in the short-term treatment of moderate-to-severe acute pain in real-world clinical practice in Asia.
Design: Real-world, prospective, multicentre, observational, phase IV study.
Setting: 13 tertiary-care hospital sites across the Philippines, Thailand, Malaysia and Singapore.
Chemoselective deoxygenative α-arylation of carboxylic acids, amides, and esters: synthesis of anesthetic and anti-inflammatory compounds.
Chem Commun (Camb)
September 2024
Department of Chemistry, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India.
A metal-free strategy has been developed for the α-arylation of carboxylic acids, secondary amides, and esters employing arenes as key reagents. This process entails the Lewis-acid catalyzed reductive Friedel-Crafts alkylation of arenes utilizing α-ketoacids, facilitated by silane in HFIP solvent. The transformation exhibits exceptional functional group tolerance, enabling late-stage functionalization of natural products.
View Article and Find Full Text PDFQuinolinyl-based multitarget-directed ligands with soluble epoxide hydrolase and fatty acid amide hydrolase inhibitory activities: Synthetic studies and pharmacological evaluations.
Heliyon
June 2024
Department of Chemistry & Biochemistry, California State University, Fullerton, 800 N. State College, Fullerton, CA, 92834, United States.
Article Synopsis
- Researchers developed a new small molecule that simultaneously inhibits two enzymes, soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH), to treat inflammatory pain.
- The study involved creating 7 different quinolinyl-based inhibitors using a specialized chemical reaction, and these were tested for effectiveness in blocking both enzymes in various animal models.
- One particularly potent inhibitor outperformed the standard drug Warfarin in stability tests and showed comparable pain relief to the painkiller ketoprofen in male rats, highlighting its potential for future therapeutic applications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!